Law360, New York (December 10, 2014, 6:36 PM EST) -- The U.S. Judicial Panel on Multidistrict Litigation on Wednesday rejected a bid by plaintiffs to consolidate more than two dozen suits over Eli Lilly & Co.'s antidepressant Cymbalta, which they claim causes serious health problems the drugmaker misled consumers about.
The JPML rejected the plaintiffs' bid to consolidate the suits in California, finding that centralizing the cases would not be efficient with cases that were in different developmental stages, according to its opinion. Some of the earliest cases in the dispute were filed around mid-2013, and are dealing with discovery matters, while several of the newer cases are "still in their...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!